{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:20:22Z","timestamp":1792603222518,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Spanish Academy of Dermatology and Venereology","id":[{"id":"https:\/\/ror.org\/01cp5nb60","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Galderma S.L."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Onychomycosis is a common fungal nail infection that responds poorly to antifungals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To investigate the efficacy and safety of methyl aminolevulinate (\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      ) photodynamic therapy (\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      ) in the treatment of onychomycosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A multicentre (3), randomized, placebo\u2010controlled clinical trial compared the effects of three sessions of urea (40%) plus conventional\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      with urea (40%) plus placebo (red light) photodynamic therapy (\n                      <jats:styled-content style=\"fixed-case\">pPDT<\/jats:styled-content>\n                      ) in onychomycosis patients. Efficacy, both clinical (onychomycosis severity index,\n                      <jats:styled-content style=\"fixed-case\">OSI<\/jats:styled-content>\n                      ) and microbiological, was blindly evaluated after 36 weeks of follow\u2010up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty patients were analysed in the trial. Twenty\u2010two received\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      and 18\n                      <jats:styled-content style=\"fixed-case\">pPDT<\/jats:styled-content>\n                      . A complete response (\n                      <jats:styled-content style=\"fixed-case\">OSI<\/jats:styled-content>\n                      = 0) was observed for four patients (18.18%) in the\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      group and one (5.56%) in the\n                      <jats:styled-content style=\"fixed-case\">pPDT<\/jats:styled-content>\n                      group (\n                      <jats:styled-content style=\"fixed-case\">NTT<\/jats:styled-content>\n                      7.92, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      : 2.98\u20139.69,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.23). A decrease in\n                      <jats:styled-content style=\"fixed-case\">OSI<\/jats:styled-content>\n                      score of over 75% (\n                      <jats:styled-content style=\"fixed-case\">OSI<\/jats:styled-content>\n                      75) was achieved by 40.91% of the patients in the\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      group and 16.67% in the\n                      <jats:styled-content style=\"fixed-case\">pPDT<\/jats:styled-content>\n                      group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.096). Microbiological cure was achieved by seven patients (31.82%) in the\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      group and two (11.11%) in the\n                      <jats:styled-content style=\"fixed-case\">pPDT<\/jats:styled-content>\n                      group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.178).\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      resulted in better rates of clinical response [\n                      <jats:styled-content style=\"fixed-case\">OSI<\/jats:styled-content>\n                      &gt;75%: 53.85% vs. 18.75% (\n                      <jats:italic>P<\/jats:italic>\n                      =0.048)] and microbiological cure [41.56% vs. 7.14% (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.037)] in non\u2010dystrophic vs. dystrophic onychomycosis patients. No significant side\u2010effects were reported. The limitations of the study were the reduced sample size and the unexpected efficacy of the control treatment, which was attributed to the 40% urea pre\u2010treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study did not show significant differences between urea 40% +\n                      <jats:styled-content style=\"fixed-case\">MAL<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>\n                      and urea 40% +\n                      <jats:styled-content style=\"fixed-case\">pPDT<\/jats:styled-content>\n                      in the treatment of onychomycosis. However, some results suggest that this treatment may constitute an alternative for dermatophyte and non\u2010dermatophyte mould onychomycosis in patients not eligible for systemic treatment, particularly in the absence of total nail dystrophy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.13842","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T04:51:40Z","timestamp":1470977500000},"page":"347-354","source":"Crossref","is-referenced-by-count":53,"title":["Methyl aminolevulinate photodynamic therapy for onychomycosis: a multicentre, randomized, controlled clinical trial"],"prefix":"10.1111","volume":"31","author":[{"given":"Y.","family":"Gilaberte","sequence":"first","affiliation":[{"name":"Department of Dermatology San Jorge Hospital Huesca Spain"},{"name":"Arag\u00f3n Institute of Health Science Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Robres","sequence":"additional","affiliation":[{"name":"Department of Microbiology Royo Villanova Hospital Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Fr\u00edas","sequence":"additional","affiliation":[{"name":"Department of Dermatology San Jorge Hospital Huesca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Garc\u00eda\u2010Doval","sequence":"additional","affiliation":[{"name":"Research Unit Spanish Academy of Dermatology and Venereology Foundation Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rezusta","sequence":"additional","affiliation":[{"name":"Department of Microbiology Miguel Servet University Hospital Zaragoza Spain"},{"name":"IIS Arag\u00f3n Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Aspiroz","sequence":"additional","affiliation":[{"name":"Arag\u00f3n Institute of Health Science Zaragoza Spain"},{"name":"Department of Microbiology Royo Villanova Hospital Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00349.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01288.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70047-2"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2007.01425.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.7547\/13-110.1"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.04.062"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2009.10.008"},{"key":"e_1_2_6_9_1","first-page":"795","volume-title":"Utilidad de la terapia fotodin\u00e1mica en el manejo de la onicomicosis","author":"Robres P","year":"2015"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.015"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2011.01.014"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.008"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0811"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12042"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2015.03.015"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.267"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0096-2"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.7547\/0003-0538-104.3.277"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000353667","article-title":"A multicenter, randomized, open\u2010label, controlled study comparing the efficacy, safety and cost\u2010effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film\u2010forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis","volume":"227","author":"Paul C","year":"2013","journal-title":"Dermatology"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2012.08.010"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142197"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.02.038"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12506"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630212345672"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2012.02215.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.00008.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13842","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.13842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:41:11Z","timestamp":1791276071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/jdv.13842"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13842","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,12]]}}}